Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Aprea Therapeutics, Inc. (APRE) is a Biotechnology company based in US with a market capitalization of $4.1M. Free cash flow was negative at -$12.9M. This page tracks APRE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 8 employees · IPO Oct 3, 2019
Valuation
Valuation & price
$0.93as of May 17, 2026· -50.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.33
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$4.1M
Market cap
—
Revenue growth (YoY)
-523.2%
Gross margin
-$12.9M
Free cash flow (USD)
-$14.6M
Net debt
Net cash position
18.7%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Gross margin by year
2023 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Aprea Therapeutics, Inc.'s market cap?
Aprea Therapeutics, Inc. (APRE) has a market capitalization of $4.1M.
What is APRE's P/E ratio?
A meaningful P/E ratio is not available for APRE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is APRE's price-to-book (P/B) ratio?
APRE trades at 0.33 times book value per share.
Are insiders buying APRE stock?
SEC Form 4 filings show no open-market insider buys at Aprea Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.